Jennifer Burdman

Jennifer Burdman is managing director at Sauvegarder Investment Management, focused on IP-based financing, investment and monetisation opportunities. She is an IP strategist and executive at biotechnology companies, and former partner in an international law firm.

As the former chief IP officer at a number of biotech startups, she has developed and implemented company IP strategy and counseled executive management and boards of directors on matters relating to the acquisition, protection, licensing, and enforcement of IP rights. Burdman has been a first-chair trial lawyer in complex, high-stakes litigation in patent infringement, trade secret misappropriation, and disputes involving IP.

Prior to joining Sauvegarder Investment Management, Burdman served as the chief IP officer and deputy general counsel at Valo Health, overseeing the company's IP strategy and advising leadership on IP-related matters. Her tenure at Valo saw significant developments, such as the noted licensing deal with Novo Nordisk and the acquisition of Tara Biosystems, which brought in advanced tissue engineering and disease modeling tech.

Prior to going in-house, as a trial lawyer, her noteworthy cases included a jury verdict of patent infringement related to the preservation of soft tissue grafts resulting in over $34 million in damages, a jury verdict of willful misappropriation of trade secrets relating to Kevlar with damages of over $900 million, and the successful defence of The Regents of the University of California against a patent licensee seeking expanded rights of sponsored research and licence agreements relating to compounds for the treatment of prostate cancer.